MF Researcher Database

Researchers Database

Advance

SUGIYAMA Daisuke

    Graduate School of Medical Sciences Department of Immunology　Lecturer
Last Updated :2024/06/11

Researcher Information

Research funding number

  • 90759375

J-Global ID

Research Areas

  • Life sciences / Immunology

Published Papers

MISC

  • 河野奨; 河野奨; 島田和之; 赤塚美樹; 赤塚美樹; 鬼頭邦吉; 杉山大介; 伊藤佐知子; 清井仁; 西川博嘉; 中村栄男  日本リンパ網内系学会会誌  58-  109  -109  2018/05
  • 杉山 大介; 西川 博嘉  腫瘍内科 = Clinical oncology  17-  (1)  94  -97  2016/01
  • 制御性T細胞は腫瘍抗原特異的CD8+T細胞に特徴的なアネルギー状態を誘導する(Regulatory T cells render tumor-antigen specific CD8+ T cells anergic)
    杉山 大介; 前田 優香; 西塔 拓郎; 西岡 めぐみ; Ha Danbee; 西川 博嘉; 坂口 志文  日本癌学会総会記事  73回-  J  -1103  2014/09
  • エフェクター型制御性T細胞の選択的除去による抗原特異的免疫応答の増強(Selective depletion of effector-type CD4+ regulatory T cells efficiently induces anti-tumor immune responses)
    杉山 大介; 西川 博嘉; 前田 優香; 西岡 めぐみ; 種村 篤; 片山 一朗; 江副 幸子; 金倉 譲; 坂口 志文  日本癌学会総会記事  72回-  361  -361  2013/10
  • エフェクター型制御性T細胞の選択的除去による抗原特異的免疫応答の増強
    杉山 大介; 西川 博嘉; 前田 優香; 西岡 めぐみ; 種村 篤; 片山 一朗; 江副 幸子; 金倉 譲; 坂口 志文  日本がん免疫学会総会プログラム・抄録集  17回-  98  -98  2013/07
  • 杉山 大介; 西川 博嘉  医学のあゆみ  244-  (9)  800  -807  2013/03

Research Grants & Projects

  • 日本学術振興会：科学研究費助成事業
    Date (from‐to) : 2022/04 -2025/03 
    Author : 杉山 大介
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research
    Date (from‐to) : 2019/04 -2022/03 
    Author : Sugiyama Daisuke
     
    We need specific receptors to sense temperature. In this study, we focused on the TRPV1 receptor, which is known to enhance immune responses, and examined whether activated TRPV1 signaling enhances the efficacy of cancer immunotherapy. The results showed that administration of capsaicin, a TRPV1 ligand, to tumor-bearing mice augmented the therapeutic effect of anti-PD-1 antibody immunotherapy, suggesting the activation of CD8-positive T cells and antigen-presenting cells by enhancing TRPV1 signaling. The results of this study suggest that the TRPV1 signaling enhancement mechanism may be a new therapeutic approach for patients who do not respond to immunotherapy.
  • Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Research Activity Start-up
    Date (from‐to) : 2015/08 -2017/03 
    Author : Sugiyama Daisuke; Nishikawa Hiroyoshi; Doi Toshihiko
     
    A cancer immunotherapy using the immune systems attracts attention as a therapeutic method to novel cancer therapy. In this study, we analyzed immune responses of the stomach-cancer patient and was intended that we got knowledge to be connected for development of the new cancer immunotherapy. After analyzing the immune cells in a blood or tumor tissue of the stomach cancer patients, there were more ratios of regulatory T cells which suppressed anti-tumor immune responses in the tumor tissues than blood, and they highly expressed cell surface molecules such as ICOS or CTLA-4. From these results, we suggested that expect an improvement effect of the anti-tumor immune responses by the removal of the regulatory T cells by ICOS and CTLA-4 marker.

Other link

researchmap


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.